Medicals Direct Screenings Limited
Annual Report and Financial Statements
For the year ended 31 December 2025
Company Registration No. 02706045 (England and Wales)
Medicals Direct Screenings Limited
Company Information
Directors
J Benton
S Paterson
(Appointed 24 September 2025)
Company number
02706045
Registered office
Unit 10 Millars Brook Business Park
Molly Millars Lane
Wokingham
Berkshire
RG41 2AD
Auditor
Moore Kingston Smith LLP
Orbital House
20 Eastern Road
Romford
Essex
RM1 3PJ
Medicals Direct Screenings Limited
Contents
Page
Directors' report
1
Directors' responsibilities statement
2
Independent auditor's report
3 - 7
Profit and loss account
8
Balance sheet
9
Notes to the financial statements
10 - 18
Medicals Direct Screenings Limited
Directors' Report
For the year ended 31 December 2025
Page 1

The directors present their annual report and financial statements for the year ended 31 December 2025.

Principal activities

The principal activity of the company continued to be that of providing health screening information for the

life insurance industry.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

J Benton
D Oatley
(Resigned 24 September 2025)
S Paterson
(Appointed 24 September 2025)
Auditor

In accordance with the company's articles, a resolution proposing that Moore Kingston Smith LLP be reappointed as auditor of the company will be put at a General Meeting.

Statement of disclosure to auditor

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the company’s auditor is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the company’s auditor is aware of that information.

Small companies exemption

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

On behalf of the board
J Benton
Director
2 July 2026
Medicals Direct Screenings Limited
Directors' Responsibilities Statement
For the year ended 31 December 2025
Page 2

The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;

- make judgements and accounting estimates that are reasonable and prudent; and

- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Medicals Direct Screenings Limited
Independent Auditor's Report
To the Members of Medicals Direct Screenings Limited
Page 3
Opinion

We have audited the financial statements of Medicals Direct Screenings Limited (the 'company') for the year ended 31 December 2025 which comprise the Profit and Loss Account, the Balance Sheet and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the company's affairs as at 31 December 2025 and of its loss for the year then ended;

- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and

- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Medicals Direct Screenings Limited
Independent Auditor's Report (Continued)
To the Members of Medicals Direct Screenings Limited
Page 4

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

- the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and

- the Directors' Report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identifie d material misstatements in the Directors' R eport. We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or

- the financial statements are not in agreement with the accounting records and returns; or

- certain disclosures of directors' remuneration specified by law are not made; or

- we have not received all the information and explanations we require for our audit; or

- the directors were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemption in preparing the Directors' Report and from the requirement to prepare a Strategic Report.

Responsibilities of directors

As explained more fully in the Directors' R esponsibilities S tatement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Medicals Direct Screenings Limited
Independent Auditor's Report (Continued)
To the Members of Medicals Direct Screenings Limited
Page 5
Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the company’s internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.

- Conclude on the appropriateness of the directors’ use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Medicals Direct Screenings Limited
Independent Auditor's Report (Continued)
To the Members of Medicals Direct Screenings Limited
Page 6

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the company.

Our approach was as follows:

- We obtained an understanding of the legal and regulatory requirements applicable to the company and considered that the most significant are the Companies Act 2006, UK financial reporting standards as issued by the Financial Reporting Council, and UK taxation legislation.

- We obtained an understanding of how the company complies with these requirements by discussions with management and those charged with governance.

- We assessed the risk of material misstatement of the financial statements, including the risk of material misstatement due to fraud and how it might occur, by holding discussions with management and those charged with governance.

- We inquired of management and those charged with governance as to any known instances of non-compliance or suspected non-compliance with laws and regulations.

- Based on this understanding, we designed specific appropriate audit procedures to identify instances of non-compliance with laws and regulations. This included making enquiries of management and those charged with governance and obtaining additional corroborative evidence as required.

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

Medicals Direct Screenings Limited
Independent Auditor's Report (Continued)
To the Members of Medicals Direct Screenings Limited
Page 7

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Karen Wardell
Senior Statutory Auditor
for and on behalf of Moore Kingston Smith LLP
2 July 2026
Chartered Accountants
Orbital House
Statutory Auditor
20 Eastern Road
Romford
Essex
RM1 3PJ
Medicals Direct Screenings Limited
Profit and Loss Account
For the year ended 31 December 2025
Page 8
2025
2024
Notes
£
£
Turnover
110,368
3,137,203
Cost of sales
(133,627)
(2,465,439)
Gross (loss)/profit
(23,259)
671,764
Administrative expenses
(195,458)
(668,325)
Exceptional item
3
-
0
(768,627)
Loss before taxation
(218,717)
(765,188)
Tax on loss
(4,541)
(4,364)
Loss for the financial year
(223,258)
(769,552)

The Profit and Loss Account has been prepared on the basis that all operations are continuing operations.

Medicals Direct Screenings Limited
Balance Sheet
As at 31 December 2025
Page 9
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
6
-
0
130,600
Tangible assets
7
-
0
1,226
Investments
8
1,000
1,000
1,000
132,826
Current assets
Debtors
10
28,334
308,957
Cash at bank and in hand
3,776
13,472
32,110
322,429
Creditors: amounts falling due within one year
11
(1,212,921)
(1,411,808)
Net current liabilities
(1,180,811)
(1,089,379)
Net liabilities
(1,179,811)
(956,553)
Capital and reserves
Called up share capital
13
14,001
14,001
Share premium account
33,499
33,499
Profit and loss reserves
(1,227,311)
(1,004,053)
Total equity
(1,179,811)
(956,553)

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 2 July 2026 and are signed on its behalf by:
J Benton
Director
Company Registration No. 02706045
Medicals Direct Screenings Limited
Notes to the Financial Statements
For the year ended 31 December 2025
Page 10
1
Accounting policies
Company information

Medicals Direct Screenings Limited is a private company limited by shares incorporated in England and Wales. The registered office is Unit 10 Millars Brook Business Park, Molly Millars Lane, Wokingham, Berkshire, RG41 2AD.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

The company has net liabilities of £1,179,811 (2024: £956,553) at the balance sheet date after a loss for the year of £223,258 (2024: £769,552). The company has net current liabilities of £1,180,811 (2024: £1,089,379).

The directors have prepared and reviewed forecasts including cash flow projections for a period of 12 months from the date of signing of these financial statements and are satisfied that the Company will be able to continue in operation and meet it's liabilities as they fall due throughout this period. Inuvi Health Limited has indicated it will continue to provide further financial and other support to Medicals Direct Screenings Limited for at least the next 12 months from the date of signing of these financial statements and will not call upon repayment of the intercompany balance of £1,192,387 within that time.

At the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that are recover able.

Medicals Direct Screenings Limited
Notes to the Financial Statements (Continued)
For the year ended 31 December 2025
1
Accounting policies
(Continued)
Page 11
1.4
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a straight line basis over its expected life, which is 10 years.

For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.

1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
25% Reducing balance
Computer equipment
33% Straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.

Entities in which the company has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.

1.7
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Medicals Direct Screenings Limited
Notes to the Financial Statements (Continued)
For the year ended 31 December 2025
1
Accounting policies
(Continued)
Page 12

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.8
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.9
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Medicals Direct Screenings Limited
Notes to the Financial Statements (Continued)
For the year ended 31 December 2025
1
Accounting policies
(Continued)
Page 13
Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.10
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.11
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

1.12
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.13
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

Medicals Direct Screenings Limited
Notes to the Financial Statements (Continued)
For the year ended 31 December 2025
Page 14
2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Key sources of estimation uncertainty

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows.

Valuation of Goodwill

The annual amortisation charge for intangible assets is sensitive to changes in the estimated lives and residual values of the assets. The useful economic lives and residual values are re-assessed annually.

Goodwill impairment reviews are also performed annually. These reviews require an estimation of the value in use of the cash generating units to which goodwill has been allocated. The value in use calculation requires the entity to estimate the future cash flows expected to arise for the cash generating unit and a suitable discount rate to calculate present value.

See note 6 for the carrying amount of the intangible assets and notes 1.4 and 1.5 for the useful economic lives for each class of asset.

3
Exceptional item
2025
2024
£
£
Expenditure
Exceptional items
-
768,627

The prior year exceptional items relate to restructuring costs due to the acquisition of the company by Inuvi Health Limited.

4
Employees

The average monthly number of persons employed by the company during the year was 4 (2024: 32).

Medicals Direct Screenings Limited
Notes to the Financial Statements (Continued)
For the year ended 31 December 2025
Page 15
5
Impairments

Impairment tests have been carried out where appropriate and the following impairment losses have been recognised in profit or loss:

2025
2024
Notes
£
£
In respect of:
Goodwill
6
39,683
-
0
Recognised in:
Administrative expenses
39,683
-
6
Intangible fixed assets
Goodwill
£
Cost
At 1 January 2025 and 31 December 2025
909,175
Amortisation and impairment
At 1 January 2025
778,575
Amortisation charged for the year
90,917
Impairment losses
39,683
At 31 December 2025
909,175
Carrying amount
At 31 December 2025
-
0
At 31 December 2024
130,600

More information on impairment movements in the year is given in note 5.

Medicals Direct Screenings Limited
Notes to the Financial Statements (Continued)
For the year ended 31 December 2025
Page 16
7
Tangible fixed assets
Fixtures and fittings
Computer equipment
Total
£
£
£
Cost
At 1 January 2025
590
86,182
86,772
Additions
170
-
0
170
Disposals
(369)
(2,740)
(3,109)
At 31 December 2025
391
83,442
83,833
Depreciation and impairment
At 1 January 2025
427
85,119
85,546
Depreciation charged in the year
9
627
636
Eliminated in respect of disposals
(45)
(2,304)
(2,349)
At 31 December 2025
391
83,442
83,833
Carrying amount
At 31 December 2025
-
0
-
0
-
0
At 31 December 2024
163
1,063
1,226
8
Fixed asset investments
2025
2024
£
£
Shares in group undertakings and participating interests
1,000
1,000
9
Subsidiaries

Details of the company's subsidiaries at 31 December 2025 are as follows:

Name of undertaking
Registered office
Nature of business
Class of
% Held
shares held
Direct
Medicals Direct Screening Services Limited
Unit 10 Millars Brook Business Park, Molly Millars Lane, Wokingham, Berkshire, England, RG41 2AD
Health screening services
Ordinary
100
Medicals Direct Screenings Limited
Notes to the Financial Statements (Continued)
For the year ended 31 December 2025
Page 17
10
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
4,200
246,439
Other debtors
1,794
-
0
Prepayments and accrued income
257
35,894
6,251
282,333
2025
2024
Amounts falling due after more than one year:
£
£
Deferred tax asset (note 12)
22,083
26,624
Total debtors
28,334
308,957
11
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
12,034
46,654
Amounts owed to group undertakings
1,192,387
1,189,291
Taxation and social security
-
0
11,959
Other creditors
8,500
163,904
1,212,921
1,411,808
12
Deferred taxation

The following are the major deferred tax liabilities and assets recognised by the company and movements thereon:

Assets
Assets
2025
2024
Balances:
£
£
Accelerated capital allowances
22,083
26,624
Medicals Direct Screenings Limited
Notes to the Financial Statements (Continued)
For the year ended 31 December 2025
12
Deferred taxation
(Continued)
Page 18
2025
Movements in the year:
£
Asset at 1 January 2025
(26,624)
Charge to profit or loss
4,541
Asset at 31 December 2025
(22,083)

13
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
14,001
14,001
14,001
14,001
14
Financial commitments, guarantees and contingent liabilities

Oaknorth Bank PLC holds a fixed and floating charge over the assets of the company, as the company acts as a guarantor for the bank loan taken out by the Inuvi Group.

15
Related party transactions

The company is a wholly owned subsidiary of Inuvi Group Limited (formerly Longacre MSS Group Limited) and has taken advantage of the exemption conferred by FRS 102 not to disclose transactions with Inuvi Group Limited (formerly Longacre MSS Group Limited) or other wholly owned subsidiaries within the group.

16
Parent company

The parent company is Inuvi Health Limited, a company incorporated in England and Wales, which owns 100% of the issued share capital of the company.

The ultimate parent company is Longacre Group Limited, a company incorporated in England and Wales.

Inuvi Group Limited is the smallest group to prepare consolidated financial statements. Longacre Group Limited is the largest group to prepare consolidated financial statements which include these financial statements. Copies of the consolidated financial statements can be obtained from 1 Mercer Street, London, WC2H 9QJ.

2025-12-31 2025-01-01 false false false CCH Software CCH Accounts Production 2026.100 J Benton D Oatley S Paterson 4 02706045 2025-01-01 2025-12-31 02706045 bus:Director1 2025-01-01 2025-12-31 02706045 bus:Director3 2025-01-01 2025-12-31 02706045 bus:Director2 2025-01-01 2025-12-31 02706045 bus:RegisteredOffice 2025-01-01 2025-12-31 02706045 2025-12-31 02706045 2024-01-01 2024-12-31 02706045 core:ContinuingOperations core:Exceptional 1 2025-01-01 2025-12-31 02706045 core:Exceptional 1 2024-01-01 2024-12-31 02706045 2024-12-31 02706045 core:NetGoodwill 2025-12-31 02706045 core:NetGoodwill 2024-12-31 02706045 core:FurnitureFittings 2025-12-31 02706045 core:ComputerEquipment 2025-12-31 02706045 core:FurnitureFittings 2024-12-31 02706045 core:ComputerEquipment 2024-12-31 02706045 core:CurrentFinancialInstruments core:WithinOneYear 2025-12-31 02706045 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 02706045 core:CurrentFinancialInstruments 2025-12-31 02706045 core:CurrentFinancialInstruments 2024-12-31 02706045 core:ShareCapital 2025-12-31 02706045 core:ShareCapital 2024-12-31 02706045 core:SharePremium 2025-12-31 02706045 core:SharePremium 2024-12-31 02706045 core:RetainedEarningsAccumulatedLosses 2025-12-31 02706045 core:RetainedEarningsAccumulatedLosses 2024-12-31 02706045 core:ShareCapitalOrdinaryShareClass1 2025-12-31 02706045 core:ShareCapitalOrdinaryShareClass1 2024-12-31 02706045 core:Goodwill 2025-01-01 2025-12-31 02706045 core:FurnitureFittings 2025-01-01 2025-12-31 02706045 core:ComputerEquipment 2025-01-01 2025-12-31 02706045 core:Goodwill 2024-01-01 2024-12-31 02706045 core:NetGoodwill 2024-12-31 02706045 core:NetGoodwill 2025-01-01 2025-12-31 02706045 core:FurnitureFittings 2024-12-31 02706045 core:ComputerEquipment 2024-12-31 02706045 2024-12-31 02706045 core:Subsidiary1 2025-01-01 2025-12-31 02706045 core:Subsidiary1 1 2025-01-01 2025-12-31 02706045 core:Non-currentFinancialInstruments 2025-12-31 02706045 core:Non-currentFinancialInstruments 2024-12-31 02706045 bus:OrdinaryShareClass1 2025-01-01 2025-12-31 02706045 bus:OrdinaryShareClass1 2025-12-31 02706045 bus:OrdinaryShareClass1 2024-12-31 02706045 bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 02706045 bus:FRS102 2025-01-01 2025-12-31 02706045 bus:Audited 2025-01-01 2025-12-31 02706045 bus:FullAccounts 2025-01-01 2025-12-31 xbrli:pure xbrli:shares iso4217:GBP